Company intelligence / Profile preview

Encysive Pharmaceuticals Inc.

Houston, Texas, United Statespfizer.com ↗

Ownership: Private
Development stage: Commercial

Overview

Encysive developed Thelin (sitaxsentan sodium) for pulmonary arterial hypertension and had filed an NDA with the FDA. The company also had Argatroban, an FDA-approved drug for heparin-induced thrombocytopenia, marketed by GlaxoSmithKline.

Therapeutic areas: DermatologyPulmonologyCardiovascularNeurology
Modalities: Small molecule compounds
Industry: Biotech

Drug pipeline

2 assets

sitaxsentan

Commercial

Indications: Pulmonary arterial hypertension

1 more asset in the full pipeline.

Request access →

Partnerships

GlaxoSmithKline

Beyond the preview

Go deeper on Encysive Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Encysive Pharmaceuticals Inc..

Explore the full profile